Matritech NMP22 Test Effective, Cheap For Bladder Cancer Detection - Study
This article was originally published in The Gray Sheet
Executive Summary
Matritech will seek approval in the first half of 1999 of its NMP22 urine assay for the detection of bladder cancer in symptomatic but undiagnosed patients. The test is already approved as a tumor marker for monitoring patients previously treated for bladder cancer.